These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 22228673)
1. Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study. Crijns HJ; van Rein N; Gispen-de Wied CC; Straus SM; de Jong-van den Berg LT Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1060-6. PubMed ID: 22228673 [TBL] [Abstract][Full Text] [Related]
2. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data. Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863 [TBL] [Abstract][Full Text] [Related]
3. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States. Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625 [TBL] [Abstract][Full Text] [Related]
4. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Crijns I; Mantel-Teeuwisse A; Bloemberg R; Pinas E; Straus S; de Jong-van den Berg L Expert Opin Drug Saf; 2013 Jan; 12(1):29-38. PubMed ID: 23163396 [TBL] [Abstract][Full Text] [Related]
5. Prescription of teratogenic medications in United States ambulatory practices. Schwarz EB; Maselli J; Norton M; Gonzales R Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908 [TBL] [Abstract][Full Text] [Related]
6. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Crijns HJ; Straus SM; Gispen-de Wied C; de Jong-van den Berg LT Br J Dermatol; 2011 Feb; 164(2):238-44. PubMed ID: 20716214 [TBL] [Abstract][Full Text] [Related]
7. [Isotretinoin in childbearing women: compliance with strengthen warnings]. Autret-Leca E; Jonville-Béra AP; Szafir D; Cissoko H; Boulkroun Y; Goehrs JM Ann Dermatol Venereol; 2000 Oct; 127(10):808-13. PubMed ID: 11060382 [TBL] [Abstract][Full Text] [Related]
8. Isotretinoin and oral contraceptive use in female acne patients varies by physician specialty: analysis of data from the National Ambulatory Medical Care Survey. Landis ET; Levender MM; Davis SA; Feneran AN; Gerancher KR; Feldman SR J Dermatolog Treat; 2012 Aug; 23(4):272-7. PubMed ID: 22380867 [TBL] [Abstract][Full Text] [Related]
10. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies. Lagan BM; Dolk H; White B; Uges DR; Sinclair M Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium. Lelubre M; Hamdani J; Senterre C; Amighi K; Peres M; Schneider MP; Bugnon O; De Vriese C Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):668-673. PubMed ID: 29726056 [TBL] [Abstract][Full Text] [Related]
12. The effect of drug consultation center guidance on contraceptive use among women using isotretinoin: a randomized, controlled study. Tsur L; Kozer E; Berkovitch M J Womens Health (Larchmt); 2008 May; 17(4):579-84. PubMed ID: 18447762 [TBL] [Abstract][Full Text] [Related]
13. Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations. Boucher N; Beaulac-Baillargeon L Can Fam Physician; 2006 Mar; 52(3):338-9. PubMed ID: 16926960 [TBL] [Abstract][Full Text] [Related]
14. Accutane-exposed pregnancies--California, 1999. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2000 Jan; 49(2):28-31. PubMed ID: 10680601 [TBL] [Abstract][Full Text] [Related]
15. Isotretinoin exposure during pregnancy: a population-based study in The Netherlands. Zomerdijk IM; Ruiter R; Houweling LM; Herings RM; Sturkenboom MC; Straus SM; Stricker BH BMJ Open; 2014 Nov; 4(11):e005602. PubMed ID: 25392022 [TBL] [Abstract][Full Text] [Related]
16. [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines]. Autret E; Radal M; Jonville-Béra AP; Goehrs JM Ann Dermatol Venereol; 1997; 124(8):518-22. PubMed ID: 9740842 [TBL] [Abstract][Full Text] [Related]
17. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential. AlGhamdi KM; Khurram H; Asiri YA; Mandil A Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870 [TBL] [Abstract][Full Text] [Related]
18. "Be smart, be safe, be sure". The revised Pregnancy Prevention Program for women on isotretinoin. Perlman SE; Leach EE; Dominguez L; Ruszkowski AM; Rudy SJ J Reprod Med; 2001 Feb; 46(2 Suppl):179-85. PubMed ID: 11255826 [TBL] [Abstract][Full Text] [Related]
19. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. Mitchell AA; Van Bennekom CM; Louik C N Engl J Med; 1995 Jul; 333(2):101-6. PubMed ID: 7777014 [TBL] [Abstract][Full Text] [Related]
20. Caring for women with childbearing potential taking teratogenic dermatologic drugs. Guidelines for practice. Perlman SE; Rudy SJ; Pinto C; Townsend-Akpan C J Reprod Med; 2001 Feb; 46(2 Suppl):153-61. PubMed ID: 11255823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]